Share on Google Plus Share on Twitter Share on Facebook Share on LinkedIn Share on PInterest Share on Fark! Share on Reddit Share on StumbleUpon Tell A Friend 1 (1 Shares)  
Printer Friendly Page Save As Favorite View Favorites View Stats   2 comments

General News

With Blockbuster Pills No Longer Selling, Pharma Turns to Injections

By (about the author)     Permalink       (Page 1 of 1 pages)
Related Topic(s): ; ; ; ; ; ; ; ; ; ; (more...) ; ; , Add Tags  (less...) Add to My Group(s)

Must Read 1   News 1   Interesting 1  
View Ratings | Rate It

opednews.com Headlined to H2 3/13/13

Become a Fan
  (73 fans)
- Advertisement -

(Article changed on March 13, 2013 at 15:26)

(Article changed on March 13, 2013 at 13:41)

(Article changed on March 13, 2013 at 10:38)

It's no secret that the bloom has fallen off Pharma's rose. Blockbuster pills like Lipitor, Seroquel, Zyprexa, Singulair and Concerta have gone off patent with nothing in the pipeline to replace them. Medical journals like the Journal of the American Medical Association (JAMA) and New England Journal of Medicine (NEJM) are noticeably thinner without the Pharma ads that have leavened them for years. As ad revenues attenuate, WebMD, the voice of Pharma on the Web, is also withering on the vine and announced it would cut 250 positions in December.

As the blockbuster pill model breaks down, Pharma is pushing vaccines and injectable drugs which cost hundreds per dose, can sometimes be co-marketed through pharmacies and are not as susceptible to generic competition. Especially lucrative to Pharma are genetically modified biologic drugs that suppress the body's tumor necrosis factor (TNF). TNF-blockers, which cost around $20,000 a year, can be life saving for autoimmune diseases but life-threatening for diseases which do not warrant them! Nonetheless Pharma is marketing TNF-blockers for arthritis, back pain, skin and digestive disorders, to prevent bone thinning and even for asthma. Ka-ching.


Thanks, Big Pharma by Martha Rosenberg

Most of the TNF-blockers are linked to TB, cancers and super infections according to their labels because they suppress the immune system. One such drug, Xolair, was investigated by the FDA for links to heart attack and stroke and 77 people who took Xolair had life-threatening allergic responses in a year and a half, according to FDA reports. Still it is "recommended" for asthma by doctors who are consultants to Pharma. What?

This month, Xolair, marketed by Genentech and Novartis, was trumpeted in the New York Times for having a new possible use of treating patients with chronic hives or chronic idiopathic urticaria. If approved for the new indication, chronic idiopathic urticaria will likely became a major U.S. health problem to be advertised on TV like restless legs syndrome.

- Advertisement -

Some of the clinical tests to determine Xolair's safety were conducted at Vivra which was investigated twice by the FDA because of whistleblower reports. Trials of Xolair and at least seven other drugs were corrupted by protocol violations and outright fraud, according to a former clinical research subinvestigator who worked at the facility. Patients were pressured to participate in trials and not warned of the risks, patients' drug diaries were falsified and insurers were billed for services which were actually enriching the investigator running the trials. San Mateo, Calif.-based Vivra Asthma & Allergy was the nation's largest respiratory disease practice until a merger with Lakewood, Colo.-based Gambro in 1997 and with El Segundo, Calif.-based DaVita in 2005.

Other TNF blockers Pharma is pushing are Humira for back pain that ads now suggest might actually be an autoimmune disorder and Prolia to prevent osteoporosis.

Drugs to prevent osteoporosis have not been Pharma's finest hour. The heavily marketed bone drugs Boniva, Fosamax and Actonel are linked to esophageal cancer, osteonecrosis of the jaw, irregular heart beat, pain and actually causing the fractures they are supposed to prevent. Oops. Fosamax-maker Merck single handedly initiated the "bone scan" craze foisted on middle aged and older women and set up a bone "institute" to secure Medicare reimbursement for scans driving Fosamax sales, according to National Public Radio.

Watch for similar ruses to sell Pharma's new injectable drugs.

END

- Advertisement -

 

Martha Rosenberg is an award-winning investigative public health reporter who covers the food, drug and gun industries. Her first book, Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health, is distributed by Random (more...)
 

Share on Google Plus Submit to Twitter Add this Page to Facebook! Share on LinkedIn Pin It! Add this Page to Fark! Submit to Reddit Submit to Stumble Upon


Go To Commenting

The views expressed in this article are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.

Writers Guidelines

Contact Author Contact Editor View Authors' Articles
- Advertisement -

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Grassley Investigates Lilly/WebMD link Reported by Washington Post

The Drug Store in Your Tap Water

It's the Cymbalta Stupid

Are You Sure You're Not Psychotic Asks Shameless Drug Company?

MRSA and More. Antibiotics Linked to Obesity and Allergies, Too

Another Poorly Regulated "Derivative"--the Antidepressant Pristiq

Comments

The time limit for entering new comments on this article has expired.

This limit can be removed. Our paid membership program is designed to give you many benefits, such as removing this time limit. To learn more, please click here.

Comments: Expand   Shrink   Hide  
2 people are discussing this page, with 2 comments
To view all comments:
Expand Comments
(Or you can set your preferences to show all comments, always)

As a sufferer of Crohn's disease, I was left no op... by Guy Blake on Wednesday, Mar 13, 2013 at 7:55:19 PM
The Eli Lilly Zyprexa saga,a criminal conspiracy ... by Danny Haszard on Thursday, Mar 14, 2013 at 12:05:26 AM